Johnson & Johnson's Q3 2012 earnings call shows continued strong performance, particularly in pharmaceuticals, with double-digit growth in key segments like Immunology and Oncology.  Management highlighted new product launches and positive trends in some key markets. However, there are some cautious notes on procedure volumes, particularly in Europe, suggesting potential near-term headwinds in the medical devices segment.  The overall outlook leans positive, with strong guidance and indications of ongoing innovation.
[1]
